2016-03-15T00:00:00.000-04:00
position,-0.201331
patient enrolment,-0.201331
Michael Bailey,0.507076
patients,-0.414592
line treatment,-0.414592
tivozanib,-0.414592
pivotal study,-0.414592
company,-0.307962
cash,0.507076
Phase,-0.414592
TIVO-3 Study,-0.201331
renal cell cancer,-0.414592
quarter,-0.201331
